CTI Clinical Trial and Consulting Services Announces the Formation of CTI Clinical Trial and Consulting Services Spain SL
CTI Clinical Trial and Consulting Services
(CTI) announces the formation of CTI Clinical Trial and Consulting Services Spain, SL. This new geographic office location will allow CTI to better meet the needs of its sponsors throughout Europe. Spain has always been a key contributor to the clinical research field and, in recent years, has seen an increase in the number of clinical trials conducted in the country. The new CTI office will be located in Madrid.
“The pharmaceutical and biotechnology industries continue to be very interested in conducting clinical research in Spain due to the quality of the clinical sites, the investigators, and the data they provide,” states Timothy J. Schroeder, CTI President and CEO. “Our therapeutic areas mesh well with the type of research conducted in Spain and our new office will help us better meet the needs of our sponsors.” The CTI Madrid Office complements its clinical trial services offering in Western Europe. CTI’s EU Team, with headquarters in Ulm, Germany, has managed clinical trials in multiple EU countries for many years.
CTI has been working for more than a decade in the drug development industry in North America, Europe, and South America, specializing in clinical research programs involving critically ill patient populations.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
